Sampling the N-terminal proteome of human blood

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 10, 2010, Pages 4561-4566

  Wildes, David ^a   Wells, James A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biomarker; Plasma; Protease; Proteomics; Serum

Indexed keywords

ALBUMIN; ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN E; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; FIBRINOGEN; GELSOLIN; PLASMA PROTEIN; PLASMINOGEN; PROTEOME; SERINE PROTEASE 1; SERINE PROTEINASE; SIGNAL PEPTIDE; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ARTICLE; BLOOD; BLOOD CLOTTING; BLOOD SAMPLING; CANCER GROWTH; ENZYME ACTIVITY; HUMAN; PLASMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEOMICS; SERUM;

BLOOD PROTEINS; CHROMATOGRAPHY, LIQUID; HUMANS; MASS SPECTROMETRY; PEPTIDE FRAGMENTS; PROTEOME; PROTEOMICS; REPRODUCIBILITY OF RESULTS; STAINING AND LABELING;

EID: 77949502598     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0914495107     Document Type: Article

References (41)

1. Anderson NL, Anderson NG (2002) The human plasma proteome: History, character, and diagnostic prospects. Mol Cell Proteomics 1:845-867.
2. Liu T, et al. (2006) Evaluation of multiprotein immunoaffinity subtraction for plasma proteomics and candidate biomarker discovery using mass spectrometry. Mol Cell Proteomics 5:2167-2174.
3. Zolotarjova N, et al. (2005) Differences among techniques for high-abundant protein depletion. Proteomics 5:3304-3313.
4. Cohen MP, Clements RS (1999) Measuring glycated proteins: Clinical and methodological aspects. Diabetes Technol The 1:57-70.
5. Agard NJ, Wells JA (2009) Methods for the proteomic identification of protease substrates. Curr Opin Chem Biol 13:503-509.
6. Doucet A, et al. (2008) Metadegradomics: Toward in vivo quantitative degradomics of proteolytic post-translational modifications of the cancer proteome. Mol Cell Proteomics 7:1925-1951.
7. Abrahmsen L, et al. (1991) Engineering subtilisin and its substrates for efficient ligation of peptide bonds in aqueous solution. Biochemistry 30:4151-4159.
8. Atwell S, Wells JA (1999) Selection for improved subtiligases by phage display. Proc Natl Acad Sci USA 96:9497-9502.
9. Chang TK, Jackson DY, Burnier JP, Wells JA (1994) Subtiligase: A tool for semisynthesis of proteins. Proc Natl Acad Sci USA 91:12544-12548.
10. Mahrus S, et al. (2008) Global sequencing of proteolytic cleavage sites in apoptosis by specific labeling of protein N termini. Cell 134:866-876.
11. Hortin GL, Sviridov D, Anderson NL (2008) High-abundance polypeptides of the human plasma proteome comprising the top 4 logs of polypeptide abundance. Clin Chem 54:1608-1616.
12. Elias JE, Haas W, Faherty BK, Gygi SP (2005) Comparative evaluation of mass spectrometry platforms used in large-scale proteomics investigations. Nat Methods 2:667-675.
13. States DJ, et al. (2006) Challenges in deriving high-confidence protein identifications from data gathered by a HUPO plasma proteome collaborative study. Nat Biotechnol 24:333-338.
14. Brown JL, Roberts WK (1976) Evidence that approximately eighty per cent of the soluble proteins from ehrlich ascites cells are N-alpha-acetylated. J Biol Chem 251:1009-1014.
15. Timmer JC, et al. (2007) Profiling constitutive proteolytic events in vivo. Biochem J 407:41-48.
16. Yi J, Kim C, Gelfand CA (2007) Inhibition of intrinsic proteolytic activities moderates preanalytical variability and instability of human plasma. J Proteome Res 6:1768-1781.
17. Page MJ, Macgillivray RTA, Di Cera E (2005) Determinants of specificity in coagulation proteases. J Thromb Haemost 3:2401-2408.
18. Sim RB, Tsiftsoglou SA (2004) Proteases of the complement system. Biochem Soc Trans 32:21-27.
19. Schwartz D, Gygi SP (2005) An iterative statistical approach to the identification of protein phosphorylation motifs from large-scale data sets. Nat Biotechnol 23:1391-1398.
20. Jackson CM, Nemerson Y (1980) Blood coagulation. Annu Rev Biochem 49:765-811.
21. Sahu A, Lambris JD (2001) Structure and biology of complement protein C3, a connecting link between innate and acquired immunity. Immunol Rev 180:35-48.
22. Hugli TE (1990) Structure and function of C3a anaphylatoxin. Curr Top Microbiol Immunol 153:181-208.
23. McDonald L, Beynon RJ (2006) Positional proteomics: Preparation of amino-terminal peptides as a strategy for proteome simplification and characterization. Nat Protocols 1:1790-1798.
24. Schilling O, Overall CM (2008) Proteome-derived, database-searchable peptide libraries for identifying protease cleavage sites. Nat Biotechnol 26:685-694.
25. Taylor RC, Cullen SP, Martin SJ (2008) Apoptosis: Controlled demolition at the cellular level. Nat Rev Mol Cell Biol 9:231-241.
26. Janowski R, Abrahamson M, Grubb A, Jaskolski M (2004) Domain swapping in N-truncated human cystatin C. J Mol Biol 341:151-160.
27. Liz MA, Gomes CM, Saraiva MJ, Sousa MM (2007) ApoA-I cleaved by transthyretin has reduced ability to promote cholesterol efflux and increased amyloidogenicity. J Lipid Res 48:2385-2395.
28. Villanueva J, et al. (2008) A sequence-specific exopeptidase activity test (SSEAT) for "functional" biomarker discovery. Mol Cell Proteomics 7:509-518.
29. Olofsson MH, et al. (2007) Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy. Clin Cancer Res 13:3198-3206.
30. Fuchs CS, et al. (2008) Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: Results from intergroup trial n9741. Clin Cancer Res 14:8263-8269.
31. Harris FM, et al. (2003) Carboxyl-terminal-truncated apolipoprotein E4 causes alzheimer's disease-like neurodegeneration and behavioral deficits in transgenicmice. Proc Natl Acad Sci USA 100:10966-10971.
32. Mizuguchi M, et al. (2008) Unfolding and aggregation of transthyretin by the truncation of 50 N-terminal amino acids. Proteins 72:261-269.
33. Keshishian H, et al. (2007) Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Proteomics 6:2212-2229.
34. Keshishian H, et al. (2009) Quantification of cardiovascular biomarkers in patient plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Proteomics 8:2339-2349.
35. Addona TA, et al. (2009) Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol 27:633-641.
36. Anderson NL, et al. (2004) Mass spectrometric quantitation of peptides and proteins using stable isotope standards and capture by anti-peptide antibodies (SISCAPA). J Proteome Res 3:235-244.
37. Marnett AB, Craik CS (2005) Papa's got a brand new tag: Advances in identification of proteases and their substrates. Trends Biotechnol 23:59-64.
38. List K, Bugge TH, Szabo R (2006) Matriptase: Potent proteolysis on the cell surface. Mol Med 12:1-7.
39. Uhland K (2006) Matriptase and its putative role in cancer. Cell Mol Life Sci 63:2968-2978.
40. Rawlings ND, et al. (2008) Merops: The peptidase database. Nucleic Acids Res 36:D320-D325.
41. Crooks GE, Hon G, Chandonia J-M, Brenner SE (2004) Weblogo: A sequence logo generator. Genome Res 14:1188-1190.